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Abstract: 
Overexposure to waterborne manganese (Mn) is linked with cognitive impairment in children 
and neurochemical abnormalities in other experimental models. In order to characterize the 
threshold between Mn-exposure and altered neurochemistry, it is important to identify 
biomarkers that positively correspond with brain Mn-accumulation. The objective of this study 
was to identify Mn-induced alterations in plasma, liver, and brain metabolites using liquid/gas 
chromatography–time of flight–mass spectrometry metabolomic analyses; and to monitor 
corresponding Mn-induced behavior changes. Weanling Sprague–Dawley rats had access to 
deionized drinking water either Mn-free or containing 1 g Mn/L for 6 weeks. Behaviors were 
monitored during the sixth week for a continuous 24 h period while in a home cage environment 
using video surveillance. Mn-exposure significantly increased liver, plasma, and brain Mn 
concentrations compared to control, specifically targeting the globus pallidus (GP). Mn 
significantly altered 98 metabolites in the brain, liver, and plasma; notably shifting cholesterol 
and fatty acid metabolism in the brain (increased oleic and palmitic acid; 12.57 and 15.48 fold 
change (FC), respectively), and liver (increased oleic acid, 14.51 FC; decreased hydroxybutyric 
acid, − 14.29 FC). Additionally, Mn-altered plasma metabolites homogentisic acid, 
chenodeoxycholic acid, and aspartic acid correlated significantly with GP and striatal Mn. Total 
distance traveled was significantly increased and positively correlated with Mn-exposure, while 
nocturnal stereotypic and exploratory behaviors were reduced with Mn-exposure and performed 
largely during the light cycle compared to unexposed rats. These data provide putative 
biomarkers for Mn-neurotoxicity and suggest that Mn disrupts the circadian cycle in rats. 
 
Article: 
INTRODUCTION 
Overexposure to environmental manganese (Mn) is known to have neurological consequences 
with symptomology similar to Parkinson's disease (PD) (Pal et al., 1999, Cersosimo and Koller, 
2006 and Perl and Olanow, 2007). Both are characterized by alterations in the dopaminergic 
system of the basal ganglia, producing movement abnormalities and cognitive deficits (Pal et al., 
1999 and Cersosimo and Koller, 2006). Mn neurotoxicity is clinically distinct from PD in that 
onset may occur at earlier ages, movement symptoms occur bilaterally as opposed to unilaterally 
in PD, and the lack of response to levo-Dopa treatment (Cersosimo and Koller, 2006). Cases of 
Mn neurotoxicity have been reported due to occupational contact (e.g., mining, battery 
manufacturing, and welding) and contaminated drinking water (Crossgrove and Zheng, 
2004 and Wasserman et al., 2006). Challenges exist in diagnosing Mn neurotoxicity, and factors 
such as length or route of exposure may differentially affect symptom onset. Inhalation of Mn 
species leads to rapid brain Mn accumulation and is associated with increased biomarkers of 
oxidative stress (Erikson et al., 2007); whereas, ingested Mn accumulates in the brain at slightly 
lower concentrations and is associated with neurochemical alterations (Garcia et al., 2006, 
Anderson et al., 2008 and Fordahl et al., 2010) and cognitive decline (Wasserman et al., 
2006 and Bouchard et al., 2011). 
 
Mn-neurotoxicity has been linked with changes in dopamine, γ-aminobutyric acid (GABA), and 
glutamate (Fitsanakis et al., 2006 for review). Mn-induced changes in these neurochemicals, 
specifically dopamine, have been associated with hyperactivity in rodents (Kern et al., 2010), 
and learning/memory deficits accompanied by changes in stereotypic behaviors in primates 
(Schneider et al., 2006 and Kern et al., 2010). Similar symptoms have been reported in Mn-
exposed children (Bouchard et al., 2007 and Farias et al., 2010), and it is imperative to identify 
symptoms of toxicity early during this critical stage of growth and neurological development. 
 
Early symptom identification and removal from Mn exposure can improve the prognosis of Mn 
neurotoxicity. The use of magnetic resonance imaging (MRI) has been demonstrated to 
accurately reflect brain Mn deposits (Dorman et al., 2006 and Fitsanakis et al., 2008), and when 
used in conjunction with positron emission tomography (PET) can identify biological alterations 
in neurotransmission (Kim et al., 1999). While MRI and PET technologies have advanced the 
identification of Mn neurotoxicity, the practical application and cost of these tools may preclude 
widespread use. Moving forward, it is important to establish cost effective diagnostic measures 
that correspond with brain Mn accumulation similar to MRI. Identifying biomarkers of Mn 
neurotoxicity in biological fluids may provide an alternative solution to confirm the extent of 
brain Mn accumulation. 
 
To date, few reliable markers exist to measure the extent of brain Mn accumulation. Prospective 
compounds such as lymphocytic manganese superoxide dismutase (MnSOD) and arginase were 
suggested as biomarkers over a decade ago; however, each possessed diagnostic limitations 
(Davis and Greger, 1992 and Brock et al., 1994). More recently, Dorman et al. (2008) screened 
for potential Mn exposure biomarkers using a liquid chromatography–mass spectrometry method 
to identify metabolomic changes in the blood and urine of monkeys exposed to airborne MnSO4. 
Of the 27 metabolites significantly altered by Mn, three blood metabolites corresponded with Mn 
accumulation in the globus pallidus (GP): phenylpyruvate, disaccharides, and guanosine 
(Dorman et al., 2008). While these markers show promise, additional studies are needed to 
confirm their potential as consistent biomarkers. 
 
The study of metabolomics is emerging as a reliable approach to identify potential biomarkers in 
diseased states including cancer (Kim et al., 2008) and amyotrophic lateral sclerosis (Pradat and 
Dib, 2009), among other potential applications (Oresic et al., 2006). Methods using liquid and 
gas chromatography, coupled with mass spectrometry (LC–MS, GC–MS), enable the detection 
of thousands of metabolites in a biological sample (Halket et al., 2005). These methods are ideal 
for monitoring changes in metabolite byproducts due to altered cellular metabolism in either a 
diseased state or after application of selected therapies. The goal of this study was to identify 
potential biomarkers of Mn neurotoxicity, and to link any changes in the metabolome with 
biological alterations associated with Mn-exposure. Additionally, we wanted to monitor any 
changes in behavior or locomotor activity indicative of neurotoxicity. While previous studies 
have examined the effects of Mn-exposure on behavior over short observational periods, to date 
no study has examined the effects of Mn on locomotor and circadian behaviors longitudinally 
over a 24 h period in a home-cage environment. A 24 h time frame allows for analysis of diurnal 
and nocturnal behaviors not normally captured with other behavioral tests. 
 
MATERIALS AND METHODS 
Animals 
Male weanling (post-natal day 21) Sprague–Dawley rats (Harlan Sprague–Dawley, Indianapolis, 
IN) (n = 12) were individually housed and randomly divided into two treatment groups: control 
(AIN-93G diet (35, 10, and 6 mg/kg Fe, Mn, and Cu, respectively) with deionized water) and 
Mn-exposed (AIN-93G diet with deionized water containing 1 g Mn (as MnCl2)/L). Formulated 
diet was obtained from Dyets Inc. (Bethlehem, PA). This Mn-exposure protocol has been used 
previously in our lab to achieve consistent brain Mn accumulation producing neurochemical 
changes indicative of toxicity after 6 weeks of exposure (Anderson et al., 2007, Anderson et al., 
2008 and Fordahl et al., 2010). Based on average water consumption for rats (10–12 mL per 
100 g body weight (Harkness and Wagner, 1989), Mn ingestion was approximately 100 mg/kg 
per day. Water levels were monitored to examine consumption, and no avoidance of Mn-
containing water was observed. Because intestinal Mn absorption in rodents is estimated at 1–5% 
(Hurley and Keen, 1987), the systemic Mn burden was approximately 1–5 mg. Human exposure 
to waterborne Mn has been reported at > 700 μg/L in children (Wasserman et al., 2006) leading 
to cognitive impairment, and up to 14 mg/L in 25 Japanese adults (Kawamura et al., 1941) 
resulting in neurotoxicity (n = 23) and death (n = 2). Although 100 mg Mn/kg is considerably 
higher than documented human exposure, it should be noted that Sprague Dawley rats have a 
higher threshold for toxicity than humans withstanding Mn doses of 200 mg/kg/day for 2 yrs and 
2251 mg/kg/day for 6 months before fatality (NTP, 1993 and Gianutsos and Murray, 1982). Rats 
had free access to food and water 24 h/day, with the lights off between 1800 and 600 h and room 
temperature maintained at 25 ± 1 °C. During the seventh week of the study, after an overnight 
fast with access to water, the rats were rendered unconscious in a CO2 chamber, euthanized via 
decapitation, brains and liver tissue removed, and trunk blood was collected for analysis. 
Dissected tissues were immediately placed on dry ice then stored at − 80 °C until analysis. For 
metal analysis, sections of the globus pallidus (GP) and striatum, two regions known to 
accumulate Mn, were removed, and the remaining brain tissue was used for metabolomic 
analysis. The University of North Carolina at Greensboro Animal Care and Use Committee 
approved all of the animal procedures. 
 
Hematology 
Trunk blood from each rat was collected in heparinized tubes and stored on ice until processed. 
Hematocrit was determined by centrifugation of heparinized micro-hematocrit capillary tubes 
(Fisher Scientific, Waltham, MA). Remaining whole blood samples were centrifuged for 15 min 
at 1000 ×g to separate plasma for iron (Fe) status assays, metabolomic analysis and metal 
quantification. Plasma was stored at − 80 °C. Plasma ferritin and transferrin were determined 
using enzyme linked immunosorbent assay (ELISA) kits from (ICL, Inc., Newberg, OR) and 
(GenWay Biotech, Inc., San Diego, CA), respectively. 
 
Behavior analysis 
Behavior analysis was conducted using Clever Systems Home Cage Scan (HCS) system (Reston, 
VA) rather than a rating scale system, which are generally time-consuming and provide ordinal 
data (Flagel and Robinson, 2007). The HCS system utilizes video images from the home cage 
acquired at 30 frames per second. Software algorithms then categorize the images into a set of 
behaviors by extracting the image of the animal movements. Based on the sequential postures of 
the animal and position of body parts in space, behaviors are assigned using pre-trained data sets 
as a reference (Flagel and Robinson, 2007). Agreement between behaviors identified by the HCS 
and manual assessments has been found to be ≥ 90% (Steele et al., 2007). During weeks four, 
five, and six of the dietary protocol, animals were placed in individual shoebox cages with food, 
water, and minimal bedding. The animals were allowed to acclimate to the novel environment 
for a 24 h period to ensure that any behavior alterations captured were treatment effects. After 
the acclimation period the animals were monitored by video surveillance and their behaviors 
were analyzed for an additional 24 h period to capture the entire light and dark cycle. Cameras 
were mounted onto tripods and placed parallel to the shoebox cages. Red lighting was utilized 
during the dark phase to provide an appropriate background for the HCS system to analyze 
movement. Behaviors were scored by the HCS system and data exported to MS Excel 2007 for 
analysis. The following behaviors were examined: total distance traveled, repetitive turning 
(turning), sniffing, rearing, and grooming. 
 
Metal analyses 
Mn, Fe, and copper (Cu) concentrations were measured with graphite furnace atomic absorption 
spectrometry (Varian AA240, Varian, Inc., USA). Brain, liver, and plasma samples were 
digested in ultra-pure nitric acid (1:10 dilution for plasma, 1:10 w/v dilution for tissue) for 48–
72 h in a sand bath (60 °C). A 50 μL aliquot of digested sample was further diluted 1:20 with a 
2% nitric acid solution for analysis. Bovine liver (NBS Standard Reference Material, USDC, 
Washington, DC) (10 μg Mn/g; 184 μg Fe/g; 80 μg Cu/g) was digested in ultrapure nitric acid 
and used as an internal standard for analysis (final concentration 5 μg Mn/L; 92 μg Fe/L; 40 μg 
Cu/L). Metal data are expressed as μg/g tissue or μg/L plasma. Additionally, an Fe:Mn ratio was 
also used to address the relationship between these metals as levels of one may impact the 
functionality or availability of the other (Chua and Morgan, 1996, Cowan et al., 
2009 and Fitsanakis et al., 2008). 
 
Liquid chromatography–time of flight mass spectrometry (LC–TOFMS) 
Plasma samples were thawed and centrifuged at 13,000 rpm for 5 min. A volume of 100 μL 
supernatant was mixed with 400 μL of a mixture of methanol and acetonitrile (5:3). The mixture 
was vortexed for 2 min, allowed to stand for 10 min, centrifuged at 13,000 rpm for 20 min, and 
then the supernatant was used for LC–TOFMS. Liver and brain tissues (100 mg and 50 mg, 
respectively) were added to 500 μL of a chloroform, methanol, and water mixture (1:2:1, v/v/v). 
These samples were then homogenized and centrifuged at 13,000 rpm for 10 min at 4 °C. A 
150 μL aliquot of supernatant was transferred to a sampling vial. The deposit was re-
homogenized with 500 μL methanol followed by a second centrifugation. Another 150 μL 
supernatant was added to the same vial for drying and then reconstituted in 500 μL of ACN:H2O 
(6:4, v/v) before separation. 
 
An Agilent HPLC 1200 system equipped with a binary solvent delivery manager and a sample 
manager (Agilent Corporation, Santa Clara, CA, USA) was used with chromatographic 
separations performed on a 4.6 × 150 mm 5 μm Agilent ZORBAX Eclipse XDB-C18 
chromatography column. The LC elution conditions are optimized as follows: isocratic at 1% B 
(0–0.5 min), linear gradient from 1% to 20% B (0.5–9.0 min), 20–75% B (9.0–15.0 min), 75–
100% B (15.0–18.0 min), isocratic at 100% B (18–19.5 min); linear gradient from 100% to 1% B 
(19.5–20.0 min) and isocratic at 1% B (20.0–25.0 min). For positive ion mode (ESI +) where A 
= water with 0.1% formic acid and B = acetonitrile with 0.1% formic acid, while A = water and 
B = acetonitrile for negative ion mode (ESI −). The column was maintained at 30 °C as a 5 μL 
aliquot of sample is injected. Mass spectrometry is performed using an Agilent model 6220 MSD 
TOF mass spectrometer equipped with a dual sprayer electrospray ionization source (Agilent 
Corporation, Santa Clara, CA, USA). The system was tuned for optimum sensitivity and 
resolution using an Agilent ESI-L low concentration tuning mix in both positive (ES +) and 
negative (ES −) electrospray ionization modes. Agilent API-TOF reference mass solution kit was 
used to obtain accurate mass time-of-flight data in both positive and negative mode operation. 
The TOF mass spectrometer was operated with the following optimized conditions: (1) ES + 
mode, capillary voltage 3500 V, nebulizer 45 psig, drying gas temperature 325 °C, drying gas 
flow 11 L/min, and (2) ES − mode, similar conditions as ES + mode except the capillary voltage 
was adjusted to 3000 V. The TOF mass spectrometer is calibrated routinely in ES + and ES − 
modes using the Agilent ESI-L low concentration tuning mix. During metabolite profiling 
experiments, both plot and centroid data are acquired for each sample from 50 to 1000 Da over a 
25 min analysis time. Data generated from LC–TOFMS were centroided, deisotoped, and 
converted to mzData xml files using the MassHunter Qualitative Analysis Program (vB.03.01) 
(Agilent). Following conversion, xml files are analyzed using the open source XCMS package 
(v1.16.3) (http://metlin.scripps.edu), which runs in the statistical package R (v.2.9.2) 
(http://www.r-project.org), to pick, align, and quantify features (chromatographic events 
corresponding to specific m/z values and elution times). The software is used with default 
settings as described (http://metlin.scripps.edu) except for xset (bw = 5) and rector (plottype = 
“m”, family = “s”). The created .tsv file is opened using Excel software and saved as .xls file. 
The resulting 3-D matrix containing arbitrarily assigned peak index, retention time, and 
abundance value (.xls file) are further exported to SIMCA-P software 12.0 (Umetrics, Umeå, 
Sweden) for multivariate statistical analysis. Compound identification was performed by 
comparing the accurate mass and retention time with reference standards available in our 
laboratory, or comparing the accurate mass with online database such as the Human Metabolome 
Database (HMDB, 2011). 
 
Gas chromatography–time of flight mass spectrometry (GC–TOFMS) 
The GC–TOFMS analysis procedure was followed by our preious publications (Qiu et al., 
2009 and Pan et al., 2010). For plasma sample (50 μL for each sample), the metabolites was 
extracted by 150 μL of mixture solvent (methanol:chloroform (3:1)). After centrifugation, an 
aliquot of the 170-μL supernatant was transferred to a glass sampling vial to vacuum dry at room 
temperature. The tissue samples were prepared identically to those used in the LC–TOFMS 
without reconstitution in ACN:H2O. Instead, the 150 μL alipuot of supernatant was added to the 
same vial (containing 10 μL heptadecanoic acid in methanol, 1 mg/mL) to vacuum dry at room 
temperature. The residue of plasma and tissue samples was then derivatized by adding 80 μL 
methoxyamine (15 mg/mL in pyridine) to the vial while holding at 30 °C for 90 min, then 10 μL 
retention index compounds (the mixture of C10-C40, 50 μg/mL) and 80 μL BSTFA (1%TMCS) 
were added into the reaction vials. Then the samples were subjected to a 70 °C for 120 min 
derivatization reaction. 
 
A 1 μL aliquot of the derivatized solution was injected using splitless mode into an Agilent 
7890 N gas chromatograph coupled with a Pegasus HT time-of-flight mass spectrometer (Leco 
Corporation, St Joseph, USA). Separation was achieved on a DB-5 ms capillary column 
(30 m × 250 μm I.D., 0.25-μm film thickness; Agilent J&W Scientific, Folsom, CA, USA), with 
helium as the carrier gas at a constant flow rate of 1.0 mL/min. The temperature of injection, 
transfer interface, and ion source was set to 260 °C, 260 °C, and 210 °C, respectively. The GC 
temperature programming was set to 2 min isothermal heating at 80 °C, followed by 10 °C/min 
oven temperature ramps to 220 °C, 5 °C/min to 240 °C, and 25 °C/min to 290 °C, and a final 
8 min maintenance at 290 °C. Electron impact ionization (70 eV) at full scan mode (m/z 40–600) 
was used, with an acquisition rate of 20 spectra/s in the TOFMS setting. The acquired MS files 
from GC/TOFMS analysis were exported in NetCDF format by ChromaTOF software (v4.22, 
Leco Co., CA, USA). CDF files were extracted using custom scripts (revised Matlab toolbox 
hierarchical multivariate curve resolution (H-MCR), developed by Par Jonsson, et al.) in the 
MATLAB 7.0 (The MathWorks, Inc, USA) for data pretreatment procedures such as baseline 
correction, de-noising, smoothing, alignment, time-window splitting, and multivariate curve 
resolution (based on multivariate curve resolution algorithm). The resulting three dimension data 
set includes sample information, peak retention time and peak intensities. Internal standards and 
any known artificial peaks, such as peaks caused by noise, column bleed and BSTFA 
derivatization procedure, were removed from the data set. The resulting data was mean centered 
and unit variance scaled during chemometric data analysis in the SIMCA-P 12.0 Software 
package (Umetrics, Umeå, Sweden). Compound identification was performed by comparing the 
mass fragments with NIST 05 Standard mass spectral databases in NIST MS search 2.0 (NIST, 
Gaithersburg, MD) software with a similarity of more than 70% and finally verified by available 
reference compounds. 
 
Data analyses 
Metal, body weight, hematology, and behavior data were analyzed using SPSS v14 for 
Windows. Data were examined for normality of distribution using a one-sample Kolmogorov–
Smirnov test and for the presence of outliers by boxplot analysis. Independent t-test analyses 
were conducted to identify changes between control and Mn-exposed groups for metal, body 
weight, hematology, and behavior data. After Bonferroni correction for multiple comparisons, 
the significance level for metal and behavior t-tests was set at p < 0.025 and p < 0.01, 
respectively. Pearson's correlational analyses were then performed to examine relationships 
between metal concentrations, biomarkers, and behaviors, with a significance threshold set at 
p < 0.05. 
 
Metabolomic LC/GC–TOFMS data was analyzed using principle component analysis (PCA) and 
OPLS analysis between groups. The differential metabolites were selected when they meet the 
requirements of variable importance in the projection (VIP) > 1 in OPLS model and p < 0.05 
from student t-test. The corresponding fold change shows how these selected differential 
metabolites varied from control. Final data analysis between control and Mn-exposed groups for 
each metabolite was conducted using independent t-test analysis with a p < 0.05 significance 
threshold. 
 
RESULTS 
Body weight and hematology 
Oral Mn-exposure alters systemic markers of iron status. Body weight measurements were 
completed three times per week to monitor growth. No significant change in body weight was 
observed between groups throughout the study, or in terminal body weight (Table 1). Because of 
the close relationship between biological Mn and Fe levels, we examined changes in 
hematological indicators of overall iron status due to Mn exposure. Mn-exposed rats had normal 
hematocrit levels but had significantly increased (p = 0.016) plasma transferrin accompanied by 
a trend toward reduced ferritin (Table 1) suggesting early stages of iron deficiency. 
 
Table 1: Body weight and hematology. 
Treatment Body Wt. (g) Hematocrit Transferrin (mg/mL) Ferritin (ng/mL) 
Control 278.7 ± 6.3 0.50 ± 0.01 1.53 ± 0.06 425 ± 47.8 
Manganese 263.3 ± 5.9 0.51 ± 0.01 2.21 ± 0.21* 299 ± 44.6 
Values are listed ± SEM and significance was established using independent t-tests to identify differences between the control (n = 6) and Mn-
exposed (n = 6) groups. 
*(p ≤ 0.05). 
 
Metal analyses 
Oral Mn-exposure led to significantly elevated brain, liver, and plasma Mn concentrations. 
Mn, Fe, and Cu were quantified in dissected brain regions of Mn-exposed rats and non-exposed 
controls. Mn accumulated significantly in the striatum and GP (p = 0.003; p = 0.019, 
respectively) of Mn-exposed rats compared to controls (Table 2). Brain Fe levels were largely 
unaffected by Mn-exposure; however, due to Mn accumulation the Fe:Mn ratio was significantly 
lower in the striatum of Mn-exposed animals compared to controls (Table 2). While Fe 
homeostasis in the GP was quite stable under Mn exposure, Cu levels were significantly elevated 
(p = 0.05) due to Mn (Table 2). Although the Fe:Mn ratio was significantly lower in many brain 
regions, stable Fe levels suggest that metabolic and behavioral changes are driven by Mn 
accumulation, not Fe deficiency. 
 
Table 2: Metal analysis of brain, liver, and plasma. 
 Brain μg/g tissue 
 Mn Fe Cu Fe:Mn ratio 
Striatum     
 Control 0.34 ± 0.06 6.1 ± 1.2 1.5 ± 0.2 21:1 
 Manganese 0.69 ± 0.06* 6.4 ± 1.3 1.5 ± 0.2 9:1* 
Globus pallidus     
 Control 0.57 ± 0.06 7.5 ± 1.8 0.9 ± 0.2 12:1 
 Manganese 1.03 ± 0.10* 9.5 ± 0.9 1.3 ± 0.1* 9:1 
 Liver μg/g tissue 
Control 2.31 ± 0.06 256 ± 31.1 4.3 ± 0.3 111:1 
Manganese 5.10 ± 0.43* 92.6 ± 21.3* 4.4 ± 0.2 18:1** 
 Plasma μg/L 
Control 8.32 ± 0.35 1543 ± 112 838 ± 19 186:1 
Manganese 26.5 ± 4.49* 1504 ± 256 848 ± 32 57:1* 
Values are listed ± SEM and data were analyzed using independent t-tests to identify differences in metal content between the Mn (n = 6) and 
control (n = 6) groups. 
*(p ≤ 0.025). **(p < 0.001). 
Similar to the brain, significantly higher Mn content was found in the liver of Mn-exposed rats 
compared to controls (p = 0.002) (Fig. 2). Elevated liver Mn was accompanied by dramatically 
reduced liver Fe levels (p = 0.012) and Fe:Mn ratio (p < 0.001) due to Mn-exposure. These data 
along with the transferrin and ferritin results indicate that Mn alters systemic Fe status leading to 
deficiency, without anemia. Liver Cu levels were comparable between Mn and control groups. 
 
 
Figure 1: OPLS of plasma spectral data — A) Gas chromatography–time of flight–mass 
spectroscopy (GC–TOFMS) data represented by OPLS-DA scores plot between control and Mn-
exposed groups. OPLS-DA Model: Control vs Mn, 1 + 2 components, R2X (cum) = 0.542, 
R2Xp = 0.152, R2Y (cum) = 0.977, Q2(cum) = 0.652. B) Liquid chromatography–time of flight 
mass spectroscopy (LC–TOFMS) data represented by the OPLS scores plot of the separation 
between healthy control and Mn-exposed rats. OPLS model: 2 component model, R2X = 0.395, 
R2Y = 0.934, Q2(cum) = 0.554. 
 
Figure 2: Relationships between brain Mn and plasma metabolites — Pearson's correlational 
analysis was conducted between plasma metabolites altered by Mn and Mn levels in the striatum 
and globus pallidus (GP). Significant relationships emerged between striatal and GP Mn levels 
with A) plasma homogentisic acid, B) aspartic acid, and C) chenodeoxycholic acid, represented 
by arbitrary units (AU), and depicted in scatterplot form with best fit trendlines representing the 
Pearson's r value for each plasma metabolite and brain region's metal content. Control (Cn) 
(n = 6) and Mn (n = 6) groups were included in the analysis and are depicted by shades of gray 
on each plot. 
 
 
Plasma Mn concentrations were significantly increased in the Mn-exposed group versus control 
(p = 0.013). Plasma Fe and Cu levels were similar between groups, but the Fe:Mn ratio was 
significantly lower in Mn-exposed (p = 0.003), compared to control. 
 
Metabolomic analyses 
Mn-exposure significantly altered plasma, brain, and liver metabolites indicating a shift in 
the metabolome compared to controls. Metabolomic analysis of these tissues using LC/GC–
TOFMS identified 98 significantly altered metabolites due to Mn-exposure. Significant changes 
were observed in each compartment: plasma (Table 3), brain (Table 4), and liver (Table 6), 
indicating changes in lipid and amino acid metabolism. Similarly, OPLS plots of plasma (Fig. 1), 
brain (Fig. 3), and liver (Fig. 4) data identify a shift in the metabolome of animals exposed to Mn 
versus healthy controls. 
 
Table 3: Plasma metabolites altered with Mn-exposure. 
Compound FC p 
Cholesterol 1.35 0.008 
2-Aminobutyric acid 1.24 0.043 
2-Ethyl-3-hydroxypropionic acid 1.52 0.015 
3,4-Dihydroxybutanoic acid 1.46 0.001 
3-Hydroxybutyric acid 1.48 0.015 
3-Indolepropionic acid 2.12 0.026 
4-Hydroxy-proline − 2.71 0.002 
Alanine − 2.00 0.041 
Arginine 2.39 0.009 
Aspartic acid − 2.55 0.004 
Chenodeoxycholic acid 2.98 0.000 
Creatinine − 2.50 0.009 
Histidine 1.36 0.035 
Homogentisic acid 2.39 0.009 
Isocitric acid 1.76 0.002 
Kynurenine 2.00 0.041 
Methionine 1.21 0.027 
Methyl phosphate 1.63 0.003 
Myo-inositol, phosphate 1.52 0.005 
Oxalic acid 1.29 0.043 
Phenylalanine 1.34 0.017 
Phosphate 1.83 0.014 
Pseudo uridine 1.36 0.007 
Uracil 1.31 0.023 
Listed is the fold change (FC) of each metabolite in the Mn-exposed (n = 6) compared to control (n = 6) group, and its corresponding p-statistic. 
Independent t-tests were used to identify significance between Mn-exposed and control groups. 
 
Table 4: Brain metabolites altered with Mn-exposure. 
Compound FC p 
2-Aminobutyric acid 1.28 0.010 
2-Butenedioic acid 2.12 0.030 
2-Pyrrolidone-5-carboxylic acid − 2.79 0.029 
3-Hydroxybutyric acid 1.46 0.005 
4-Guanidinobutanoic acid 1.23 0.025 
Acetyl aspartate 3.11 0.011 
Arabitol 1.63 0.048 
Ascorbic acid 1.60 0.004 
Aspartic acid − 1.10 0.024 
Carnitine − 1.10 0.011 
Cholesterol 4.42 0.033 
Citric acid 1.31 0.031 
Desmosine 12.69 0.007 
Fructose 1.41 0.028 
Glycocholic acid − 2.78 0.009 
N-Acetyl-l-aspartic acid 1.55 0.004 
Oleic acid 12.57 0.000 
Palmitic acid 15.48 0.000 
Phosphate 1.12 0.018 
Proline − 1.84 0.027 
Sarcosine 1.33 0.006 
Uracil 1.35 0.028 
Urea 2.36 0.025 
Valine 1.55 0.024 
Listed is the fold change (FC) of each metabolite in the Mn-exposed (n = 6) compared to control (n = 6) group, and its corresponding p-statistic. 
Independent t-tests were used to identify significance between Mn-exposed and control groups. 
 
 
 
 
Figure 3: OPLS of brain spectral data — A) Gas chromatography–time of flight–mass 
spectroscopy (GC–TOFMS) data represented by OPLS-DA scores plot between control and Mn-
exposed groups. OPLS-DA, Control vs Mn, 1 + 2 components, R2X (cum) = 0.462, 
R2Xp = 0.153, R2Y (cum) = 0.978, Q2(cum) = 0.526. B) Liquid chromatography–time of flight 
mass spectroscopy (LC–TOFMS) data represented by the OPLS scores plot of the separation 
between healthy control and Mn-exposed rats. OPLS model: 2 component model, R2X = 0.500, 
R2Y = 0.979, Q2(cum) = 0.642. 
 
Figure 4: OPLS of liver spectral data – A) Gas chromatography–time of flight–mass 
spectroscopy (GC–TOFMS) data represented by OPLS-DA scores plot between control and Mn-
exposed groups. OPLS-DA Model: Control vs Mn, 1 + 2 components, R2X (cum) = 0.454, 
R2Xp = 0.176, R2Y (cum) = 0.996, Q2(cum) = 0.695. B) Liquid chromatography–time of flight 
mass spectroscopy (LC–TOFMS) data represented by the OPLS scores plot of the separation 
between healthy control and Mn-exposed rats. OPLS model: 2 component model, R2X = 0.391, 
R2Y = 0.964, Q2(cum) = 0.660. 
 
 
Several plasma metabolites altered by Mn reflect amino acid breakdown. Markers of tryptophan 
metabolism, 3-indolepropionic acid and kynurenine, were significantly elevated (2.12 fold 
change (FC); p = 0.026 and 2 FC; p = 0.041, respectively). Similarly, arginine and homogentisic 
acid levels were increased due to Mn, while alanine and creatinine were significantly decreased 
(Table 3). Significant associations were also identified between regional brain Mn accumulation 
and select plasma metabolites (Fig. 2). Positive correlations were found between plasma 
homogentisic acid and Mn levels in the striatum and GP (r = 0.6980, p = 0.012 and r = 0.7155, 
p = 0.009, respectively) (Fig. 2A), as well as substantia nigra Mn, GP Cu, and GP Fe levels 
(r = 0.7068, p = 0.010; r = 0.6973, p = 0.012; and r = 0.6355, p = 0.026, respectively) (data not 
shown). Similarly, chenodeoxycholic acid was positively correlated with striatal and GP Mn 
(r = 0.7724, p = 0.003 and r = 0.7589, p = 0.004, respectively) (Fig. 2C). These changes were 
accompanied by negative correlations between plasma aspartic acid and Mn in the striatum and 
GP (Fig. 2B). Additionally, correlations between metabolite changes and brain metals represent 
potential indices for brain metal homeostasis and Mn accumulation. 
 
Mn altered brain metabolites indicative of compromised lipid metabolism and potential plasma 
membrane integrity including significant increases in cholesterol (4.42 FC; p = 0.033), 
desmosine (12.69 FC; p = 0.007), oleic acid (12.57 FC; p < 0.001), and palmitic acid (15.48 FC; 
p < 0.001) (Table 4). Changes in these lipids and several other brain metabolites were correlated 
with plasma Mn levels (Table 5). Alterations in oleic and palmitic acid may also suggest an 
impairment in fatty acid synthesis and energy metabolism, along with the significant increase in 
2-butenedioic acid “Fumarate” (2.12 FC; p = 0.030). Mn caused a significant increase in urea 
(2.36 FC; p = 0.025) and decreased 2-pyrrolidone-5-carboxylic acid (− 2.79 FC; p = 0.029), 
which could be linked to disrupted glutamine metabolism. 
 
 
Table 5: Brain metabolites correlated with plasma Mn. 
Compound r p 
2-Butenedioic acid 0.8415 < 0.001 
Cholesterol 0.6208 0.031 
Desmosine 0.8197 0.001 
Glycocholic acid − 0.6627 0.019 
Oleic acid 0.8332 < 0.001 
Palmitic acid 0.7589 0.004 
Relationships between plasma Mn and altered brain metabolites were identified using Pearson's correlational analysis. r and p values are 
displayed for each metabolite significantly (p < 0.05) correlated with plasma Mn. 
 
 
The largest effect Mn exposure had on liver metabolites pertained to lipid metabolism and ketone 
body formation; oleic acid (14.51 FC; p = 0.003) and hydroxybutyric acid (− 14.29 FC; 
p = 0.048), respectively (Table 6). Mn also significantly decreased metabolites associated with 
energy metabolism including creatine (− 3.13 FC; p = 0.008) and nicotinamide ribotide (− 3.03 
FC; p = 0.031), and structural markers hydroxyglutaric acid, desmosine, and serine (6.47 FC, 
5.25 FC, and 3.78 FC, respectively; p < 0.002) (Table 6). It is important to note that the liver 
metabolites altered by Mn-exposure were correlated with increased liver Mn concentrations and 
not decreased Fe levels (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Liver metabolites altered with Mn-exposure. 
 
Listed is the fold change (FC) of each metabolite in the Mn-exposed (n = 6) compared to control (n = 6) group, and its corresponding p-statistic. 
Independent t-tests were used to identify significance between Mn-exposed and control groups. 
 
 
Behavioral observations 
Mn-exposure significantly increased locomotion and altered stereotypic activity associated 
with light and dark cycles. Because hyperactivity and altered locomotion has been previously 
associated with Mn-exposure ( [Bouchard et al., 2007] and [Kern et al., 2010]) we conducted 
behavioral analysis during the fourth, fifth, and sixth weeks of Mn-exposure using 24 h video 
surveillance to monitor Mn-induced changes in activity. No changes in behavior occurred until 
the sixth week of exposure when total activity, measured as total distance traveled (TDT), was 
significantly greater (p = 0.003) in the Mn-exposed group (Fig. 5A); moreover, increased 
Compound FC p 
1,4-Diaminobutane 1.40 0.022 
1-Methyladenosine 1.37 0.001 
2-Aminobutyric acid 1.34 0.033 
3-Hydroxy-n-valeric acid 1.52 0.015 
Aminocaproic acid 1.15 0.013 
Aspartic acid 1.11 0.047 
But-2-enoic acid 1.24 0.000 
Cadaverine 1.93 0.008 
Choline − 1.19 0.041 
Citicoline 1.59 0.007 
Creatine − 3.13 0.008 
Cytidine 1.24 0.030 
Desmosine 5.25 0.002 
Dihydrothymine − 3.03 0.012 
d-Xylose-1-phosphate − 1.48 0.010 
Ethylmalonic acid 2.30 0.040 
Glycerolphosphate − 1.56 0.002 
Homocitrulline 1.63 0.006 
Hydroxybutyric acid − 14.29 0.048 
Hydroxyglutaric acid 6.47 0.001 
Isoleucine 2.62 0.030 
l-Cysteine 1.42 0.000 
l-Methionine 1.15 0.044 
Malonic acid − 1.32 0.014 
N,N-Dimethylglycine 1.47 0.038 
N-Acetyl glucosamine 1.22 0.042 
Nicotinamide ribotide − 3.03 0.031 
Norepinephrine 1.95 0.011 
Norleucine 1.28 0.045 
Octadecanedioic acid 1.58 0.013 
Oleamide 1.57 0.040 
Oleic acid 14.51 0.003 
Pantothenic acid 1.25 0.007 
Proline 1.55 0.006 
Pyridoxamine 1.20 0.013 
Pyroglutamic acid − 1.13 0.045 
Ribitol 1.67 0.050 
Ribonic acid-1,4-lactone 2.19 0.000 
Sebacic acid 1.15 0.018 
Serine 3.78 0.001 
Serotonin 1.27 0.034 
S-Nitrosoglutathione 1.64 0.015 
Stearic acid − 3.33 0.017 
Taurocholic acid 1.38 0.017 
Threonine 1.19 0.022 
Uracil 1.41 0.029 
Urobilin − 1.75 0.020 
Valeric acid 1.22 0.050 
Valine 1.17 0.048 
Xanthosine 1.53 0.002 
locomotion was strongly correlated with GP, striatal, and plasma Mn levels (r = 0.8027, 
p = 0.002; r = 0.7212, p = 0.008; and r = 0.6229, p = 0.030, respectively) (Fig. 5A1, A2, and 
A3). Analysis of individual behaviors identified a significant increase in repetitive turning 
(p = 0.007) during the light cycle of Mn-exposed animals and a significant Mn-induced decrease 
in rearing (p = 0.006) during the dark cycle (Fig. 5B). Depicting behaviors as percent performed 
in the light cycle versus dark cycle revealed increased activity of Mn-exposed animals in the 
light cycle, contradictory to the nocturnal activity of the controls (Fig. 5C). 
 
 
 
Figure 5: Behavioral analysis of Mn and control rats — Behaviors were monitored for 24 h 
using Home Cage Scan video surveillance during the sixth week of Mn-exposure. A) Total 
distance traveled (TDT) in meters over the 24 h period for control and Mn-exposed rats. 
Independent t-tests were used to identify differences between groups and data are 
expressed ± SEM. Inset) Scatter plot representation of Pearson's correlational analysis between 
TDT (in meters; x axis) and 1) plasma Mn (μg/L; y axis) (r = 0.6229), 2) striatal Mn (μg/g; y 
axis) (r = 0.7212), and 3) globus pallidus (GP) Mn (μg/g; y axis) (r = 0.8027). B) Total behaviors 
expressed as percent control during the light and dark cycles using independent t-tests to identify 
differences between groups data are expressed ± SEM. (* = p < 0.01) C) Percentage of each 
behavior completed in the light or dark cycle for control and Mn-exposed rats. 
 
 
DISCUSSION 
The purpose of this study was to identify biomarkers of Mn-toxicity that provide diagnostic 
information corresponding to brain Mn accumulation, and to monitor changes in rat home cage 
behaviors that accompany Mn-accumulation. Using a LC/GC–TOFMS method of metabolomic 
analysis we were able to identify several potential biomarkers that corresponded with indices of 
Mn-neurotoxicity in rats; including, altered metal homeostasis, amino acid metabolism, and 
markers of structural damage. Additionally, video surveillance identified altered behavior and 
activity consistent with previous observations in Mn-exposure models; however, our 24 h data 
collection period identified a previously unreported disturbance in circadian rhythm due to Mn-
toxicity. 
 
Oral Mn-exposure elevated brain Mn in all regions examined, primarily localizing in the GP. A 
novel increase in Cu was also observed in the GP, but it is unclear whether the elevation in Cu is 
a direct effect or an artifact of Mn-exposure. For example, Mn can influence Fe homeostasis, 
evidenced by a decrease in the Fe:Mn ratio, which has been linked with elevated GP copper 
(Erikson et al., 2004). Similarly, liver and plasma Mn levels were increased with Mn-exposure. 
While Mn-exposure did not drastically alter brain or plasma Fe levels, it did significantly lower 
liver Fe content. Decreased liver Fe was accompanied by decreased plasma ferritin and increased 
plasma transferrin indicating systemic Fe deficiency but not anemia (normal hematocrit) 
(Table 1 and Table 2). It is important to note that while systemic Fe status was significantly 
altered due to Mn exposure, the metabolic and behavior alterations that occurred were strongly 
associated with increased brain Mn content and not depleted systemic iron. 
 
Locomotor activity (i.e. total distance traveled) is often used in neuroscience as an outcome 
measure for neurotoxic effects (O'Donoghue, 1996 and Flagel and Robinson, 2007). In our study, 
increased overall activity, measured by TDT, was observed with Mn exposure, and was 
associated with plasma, striatal, and GP Mn levels (Fig. 5A). Increases in the motor activity of 
rats as a result of Mn exposure have been reported previously (Calabresi et al., 2001 and Kern et 
al., 2010), though these effects are often transient (Vacher et al., 2006). Repetitive turning was 
also observed in Mn-exposed rats, which may contribute to the overall increased activity, but has 
also been associated with stereotypy linked to dopaminergic dysfunction, akin to obsessive 
compulsive disorders (de Haas et al., 2010). While repetitive turning was significantly elevated 
in Mn-exposed rats the distribution of repetitive turning events was consistent with the circadian 
behavior of control animals, unlike rearing, sniffing and grooming (Fig. 5C). Rearing and 
sniffing behaviors were markedly decreased during the dark cycle of Mn-exposed rats, consistent 
with previous reports (Witholt et al., 2000). Changes in these exploratory behaviors contradict 
typical nocturnal behavior (Scheer et al., 2003) and suggest that Mn-exposure may disrupt the 
circadian clock. Sleep disturbances are common among Parkinson's disease patients (Suzuki et 
al., 2011), and reversal of the circadian rhythm has been observed in iron deficient rats and is 
attributed to alterations in dopaminergic and/or noradrenergic activity (Youdim et al., 1980). In 
addition to dopamine and norepinephrine, circadian rhythm is largely influenced by serotonin, 
GABA, and glutamate in the suprachiasmatic nucleus (Wagner et al., 2001 and Reghunandanan 
and Reghunandanan, 2006), and circadian fluctuations in dopamine, glutamate, and GABA have 
been reported in the striatum of rats (Castaneda et al., 2004). Therefore, if the altered light/dark 
behaviors observed in this study are indeed alterations in circadian rhythm, they are likely driven 
by alterations in striatal dopamine, GABA and/or glutamate that have been linked with Mn-
exposure (Fitsanakis et al., 2006 for review). Further studies utilizing larger sample size with 
longer monitoring periods are needed to confirm Mn-induced circadian reversal; however, these 
data suggest that Mn disrupts normal behaviors throughout the light/dark cycle as opposed to 
previously reported short observational periods (Youdim and Yehuda, 1985). While behavior is a 
valuable indicator of neurobiological function when assessing neurotoxicity; biochemical 
measures (e.g. metabolomics) are equally important to identify metabolic changes congruent 
with neurotoxicity, and to reveal potential biomarkers. 
 
To our knowledge, the only other metabolomic analysis of Mn-exposure was completed by 
Dorman et al. (2008) in monkeys exposed to airborne MnSO4. While the Mn exposure protocol 
between the two studies differed, there were similarities in altered blood metabolites, specifically 
elevated arginine and glutamine derivatives. Our study corroborated these previous data and 
revealed a few new scenarios. Possibly the most compelling identified a substantial impact of 
Mn on fatty acid metabolism in the brain. Palmitic acid, the product of de novo lipogenesis, was 
detected in 15-fold greater concentrations in the brains of Mn-exposed rats. Increased palmitate 
was accompanied by significant elevations in oleic acid, desmosine, and cholesterol (Table 4). 
Other than oleic acid, Mn did not have the same affect on these metabolites in the liver, which is 
interesting because Mn has been shown to increase lipogenesis in liver tissue despite high lipid 
availability (Baquer et al., 1974), possibly by inhibiting normal feedback mechanisms. Mn has 
also been linked to increased acetyl-CoA carboxylase activity, enhancing fatty acid synthesis 
(Scorpio and Masoro, 1970). Mn-enhanced lipogenesis could account for the increased palmitic 
acid (found in the brain) and its potential downstream product oleic acid (increased in brain and 
liver). Alternatively, Mn has been implicated in endoplasmic reticular stress (Chun et al., 
2001 and Tjalkens et al., 2006), which may disrupt fatty acid elongation resulting in abnormally 
high palmitic acid content. Mn accumulation may also compromise liver function leading to liver 
damage or failure. Mn-induced liver failure will directly affect liver metabolites and may 
influence metabolite changes in other tissues including clearance and/or degradation. 
 
Increased palmitic acid in the brain, along with elevated cholesterol, may introduce a scenario 
similar to what has been observed in Alzheimer's disease (AD). Palmitic acid has been linked to 
increase ceramide production in astrocytes (Patil et al., 2007) and implicated in the elevation of 
β-secretase (BACE1) activity and tau hyperphosphorylation (Patil et al., 2008). Additionally, 
elevated free cholesterol influences β- and γ-secretase activity enhancing amyloid β production 
(Shobab et al., 2005). Mn has also been directly linked to tau hyperphosphorylation in PC12 cells 
(Cai et al., 2011). Changes in lipid availability may also compromise membrane integrity by 
increasing fatty acid and cholesterol incorporation, thereby altering normal structure and 
dynamics. Continuity of vascular structure may also be compromised as elevated levels of 
desmosine, a marker of elastin breakdown (Ronchetti and Contri, 1997), were found in the Mn-
exposed group compared to control. 
 
Evidence of compromised integrity existed in the brains of Mn-exposed rats. We speculate, 
however, that markers of structural damage were not linked to neuronal death. Neuronal loss due 
to structural damage has been associated with decreased N-acetylaspartate (NAA) levels 
(Demougeot et al., 2001), and a previous study on Mn-exposed primates observed decreases in 
NAA and the NAA:creatine ratio suggesting neuronal integrity/density was altered (Guilarte et 
al., 2006). We observed minimal changes in brain creatine levels and increased NAA due to Mn-
exposure, and when coupled with altered lipid metabolites likely signify altered membrane 
integrity rather than neuronal death. 
 
To investigate potential biomarkers associated with Mn-induced neurological dysfunction, we 
conducted correlational analyses between the plasma metabolites prominently altered by Mn 
with brain Mn concentrations in the striatum and GP. Notable plasma metabolites that were 
altered due to Mn were aromatic amino acids derivatives (Tryptophan: 3-indolepropionic acid 
and kynurenine; Tyrosine: homogentisic acid) (Table 3). Plasma homogentisic acid, aspartic 
acid, and chenodeoxycholic acid all correlated significantly with GP and striatal Mn 
accumulation (Fig. 2). Increased chenodeoxycholic acid is consistent with altered bile acid 
regulation in the liver (Table 6). Because plasma Mn correlated significantly with GP Mn we 
also examined relationships between plasma Mn and altered brain and liver metabolites. Weak 
correlations were found between plasma Mn and liver metabolites associated with energy 
production (e.g. creatine and ribonic acid) (data not shown); however, plasma Mn was a better 
predictor of altered lipid metabolism (cholesterol, palmitate and oleate) and structural integrity 
(desmosine) in the brain. In this aspect, plasma Mn may be useful to monitor along with plasma 
metabolites (e.g., chenodeoxycholic acid or homogentisic acid) in order to gain a more complete 
picture of brain Mn accumulation and its resulting pathologies possibly leading to earlier 
intervention. 
 
In conclusion, 6 weeks of oral Mn-exposure led to increased brain Mn that corresponded with 
locomotor and stereotypic behavior abnormalities suggesting a disturbance in circadian rhythm. 
Simultaneous changes in brain, plasma, and liver metabolites were also identified and associated 
with brain Mn accumulation. Together, these data provide a useful starting point to identify 
metabolite biomarkers that correspond with Mn toxicity in a more cost effective manner. 
Furthermore, it may be prudent to consider how shifts in multiple metabolites may relate to one 
another in Mn-toxicity; for example, an indicator of brain Mn accumulation (plasma 
chenodeoxycholic acid predicts GP Mn) together with an indicator of Mn-induced changes in the 
brain (plasma Mn predicts elevated brain desmosine) will better appraise the progression of 
neurotoxicity. GC/LC–TOFMS can be a powerful tool to identify potential biomarkers, and 
additional study paradigms (route of exposure and/or species) are warranted to identify 
consistent biomarkers using this technique. 
 
ABBREVIATIONS 
Mn, manganese; PD, Parkinson's disease; GABA, γ-aminobutyric acid; MRI, magnetic 
resonance imaging; PET, positron emission tomography; MnSOD, manganese superoxide 
dismutase; GP, globus pallidus; LC–TOFMS, liquid chromatography–time of flight mass 
spectrometry; GC–TOFMS, gas chromatography–time of flight mass spectrometry; Fe, iron;  
ELISA, enzyme linked immunosorbent assay; HCS, Home Cage Scan; Cu, copper; FC, fold 
change; TDT, total distance traveled; AD, Alzheimer's disease; Cn, control; NAA, N-
acetylaspartate; HMDB, Human Metabolome Database 
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